has function has role immunizes against disease immunizes recipient test in lab animal model lymphoma Mus musculus Homo sapiens therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role lymphoma vaccine Survivin Antigen Vaccine DPX-Survivac Virginia He NCT: https://clinicaltrials.gov/ct2/show/NCT02323230 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5371 Oliver He Jimmy Guo Gene name: Survivin 5371 NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97951 A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of the maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. cancer vaccine PMID:26405584 https://github.com/vaccineontology/VO/issues/364 Jie Zheng 373110 therapeutic cancer vaccine